Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00493311 · ClinicalTrials.gov registry record · Phase 3

Safety of Intravenous Acetaminophen Vs Placebo for the Treatment of Endotoxin-Induced Fever in Healthy Adult Males

A Phase 3 study, sponsored by Mallinckrodt.

Completed
Registry status
Phase 3
Development phase
60
Enrollment target

NCT00493311 is a Phase 3 study that has completed, run by Mallinckrodt. The registered enrollment target is 60 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00493311, a Phase 3 study, has completed, sponsored by Mallinckrodt.

COMPLETED
Registry status
Phase 3
Development phase
60 participants
Enrollment target

Study Summary

A research study to determine if acetaminophen (APAP) given intravenously (IV-a liquid given through a needle into a vein in your arm) is safe and effective in controlling fever when compared to placebo. Acetaminophen given this way is the investigational part of this study.

Interventions

  • DRUG IV Placebo
  • DRUG IV Acetaminophen
  • BIOLOGICAL Reference Standard Endotoxin (RSE)

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2007-06
Est. Completion 2007-10
Phase Phase 3

Sponsor

Mallinckrodt

69 total trials

What the Registry Record Tells You About NCT00493311

The ClinicalTrials.gov registry entry for NCT00493311 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mallinckrodt, which has 69 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which IV Placebo is the first listed.

NCT00493311 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00493311 about?

NCT00493311 is a clinical study titled "Safety of Intravenous Acetaminophen Vs Placebo for the Treatment of Endotoxin-Induced Fever in Healthy Adult Males". A research study to determine if acetaminophen (APAP) given intravenously (IV-a liquid given through a needle into a vein in your arm) is safe and effective in controlling fever when compared to placebo. Acetaminophen given this way is the investigational part of this study.

What is the current status of trial NCT00493311?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2007-06. Estimated completion is 2007-10.

What interventions are being tested in trial NCT00493311?

The interventions under investigation include: IV Placebo (DRUG), IV Acetaminophen (DRUG), Reference Standard Endotoxin (RSE) (BIOLOGICAL).

Who is sponsoring clinical trial NCT00493311?

This trial is sponsored by Mallinckrodt, which has 69 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.